Results 91 to 100 of about 134,100 (245)

Primary Dural Lymphoma: Clinical Cases and Literature Review

open access: yesCase Reports in Medicine, 2020
Primary dural lymphoma (PDL) is an extranodal non-Hodgkin lymphoma that accounts for less than 1% of all central nervous system lymphomas. Primary dural lymphoma grows from the dura mater, and it is often diagnosed as meningioma or acute subdural ...
M. Dobran   +3 more
doaj   +1 more source

Emerging targets in human lymphoma: targeting the MYD88 mutation [PDF]

open access: yes, 2016
B cell neoplasms co-opt the molecular machinery of normal B cells for their survival. Technological advances in cancer genomics has significantly contributed to uncovering the root cause of aggressive lymphomas, revealing a previously unknown link ...
Horikawa, Keisuke   +2 more
core   +1 more source

Is the incidence of early‐onset cancers increasing in the northeast of Italy? A 30‐year analysis of the regional cancer registration data by age, 1987–2019

open access: yesInternational Journal of Cancer, EarlyView.
Whats New? This observational study of the incidence trends of malignancy by site, stratified by age group and sex, over three decades in a large northern Italian population reveals a heterogeneous landscape among younger adults (aged under 50). Invasive cutaneous melanoma in both sexes, testicular cancer and multiple myeloma in males, and breast ...
Alessandra Buja   +9 more
wiley   +1 more source

Diagnosis validity of AgNOR staining for differentaing non-Hodgkin lymphoma from reactive hyperplasia

open access: yesمجله دانشگاه علوم پزشکی گرگان, 2005
Background&Objective: There are different methods including H&E, imonhistochemstry, flu cytometry, AgNOR staining for differentiation reactive hyperplasia from lymphoma.
Zh.Torabizade (MD)   +2 more
doaj  

Immune Thrombocytopenia in a Child with T Cell Lymphoblastic Lymphoma

open access: yesCase Reports in Hematology, 2016
We describe the case of a 13-year-old boy who presented with persistent thrombocytopenia during maintenance chemotherapy with mercaptopurine and methotrexate for T cell lymphoblastic lymphoma.
Kayo Tokeji   +4 more
doaj   +1 more source

Non-Hodgkin and Hodgkin Lymphomas Select for Overexpression of BCLW. [PDF]

open access: yes, 2017
Purpose: B-cell lymphomas must acquire resistance to apoptosis during their development. We recently discovered BCLW, an antiapoptotic BCL2 family member thought only to contribute to spermatogenesis, was overexpressed in diffuse large B-cell lymphoma ...
Adams, Clare M.   +3 more
core   +1 more source

The risk of basal and squamous cell carcinomas of the skin cancer incidence and external radiation in the updated National Registry for radiation workers cohort in the UK

open access: yesInternational Journal of Cancer, EarlyView.
What's New? While ultraviolet radiation from the sun is the main risk factor for non‐melanoma skin cancer (NMSC), additional factors contribute to NMSC development. The present study examined the impact of occupational radiation exposure on NMSC risk among radiation workers in the United Kingdom.
Nezahat Hunter, Richard Haylock
wiley   +1 more source

Composite Lymphoma: Hodgkin and Non-Hodgkin Lymphoma A Case Report

open access: yesJurnal Penyakit Dalam Indonesia, 2018
Composite lymphoma (CL) is a rare disease. Composite lymphoma is two or more different type of lymphoma that sequentially or simultaneously occur in one anatomical site.
Noorwati Soetandyo   +3 more
doaj   +1 more source

Elevated numbers of PD-L1 expressing B cells are associated with the development of AIDS-NHL. [PDF]

open access: yes, 2019
The risk for non-Hodgkin lymphoma (NHL) is markedly increased in persons living with human immunodeficiency virus (HIV) infection, and remains elevated in those on anti-retroviral therapy (cART).
Conti, David V   +5 more
core  

Immunosenescence and lymphomagenesis [PDF]

open access: yes, 2018
One of the most important determinants of aging-related changes is a complex biological process emerged recently and called \u201cimmunosenescence\u201d.
A Beheshti   +90 more
core   +1 more source

Home - About - Disclaimer - Privacy